Singapore markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.06-0.39 (-3.13%)
At close: 04:00PM EST
12.00 -0.06 (-0.50%)
After hours: 07:55PM EST

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302

Full-time employees246

Key executives

NameTitlePayExercisedYear born
Mr. Jon P. StonehouseCEO, Pres & Exec. Director1.12M559.29k1961
Mr. Anthony J. DoyleSr. VP & CFO649.71kN/AN/A
Dr. William P. SheridanChief Medical Officer & Sr. VP786.97kN/A1955
Dr. Yarlagadda S. BabuChief Discovery Officer682.62kN/A1953
Dr. Helen M. Thackray FAAP, M.D.Chief R&D Officer55kN/A1968
Mr. Michael L. JonesExec. Director of Fin. & Principal Accounting OfficerN/AN/A1970
Mr. John D. BluthSr. VP of Investor Relations & Corp. CommunicationsN/AN/A1973
Ms. Alane P. BarnesSr. VP, Chief Legal Officer & Corp. Sec.N/AN/A1966
Mr. Robert C. StonerVP of HRN/AN/AN/A
Dr. Elliott T. BergerSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Corporate governance

BioCryst Pharmaceuticals, Inc.’s ISS governance QualityScore as of 26 September 2021 is 6. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.